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Reciprocal interactions between tumor cells and their microenvironment drive cancer progression
and therapy resistance. In this issue, Nabet et al. demonstrate that dynamic feedback between tu-
mor and stroma subverts normal inflammatory responses by triggering the release of exosomes
containing unshielded RNAs that activate pattern recognition receptors, thereby promoting tumor
growth and metastasis.During cancer progression, the tumor
and its microenvironment co-evolve, due
to constant communication. As the tu-
mor reshapes its local microenvironment,
coaxing it to support cancer growth, it
exerts systemic effects, conquering the
immune system and distant organs, lead-
ing tometastasis. The local and far-reach-
ing effects of tumors are mediated by
tumor-secreted factors, such as soluble
factors (cytokines and chemokines) and
exosomes—nanovesicles that carry com-
plex cargo, including proteins, DNA, and
coding as well as non-coding RNAs
(Becker et al., 2016).
A hallmark of cancer progression is
the generation of local and systemic
inflammation, driven by pro-inflammatory
cytokines and a shift in the balance of
both adaptive and innate immune sub-
sets toward tumor-promoting pheno-
types. Interestingly, in the absence of can-
cer, systemic inflammation is crucial for
eliminating pathogens or noxious stimuli
and repairing tissue damage (Huang
et al., 2015). While an interplay between
pathogen- and danger-associated mo-
lecular pattern (DAMP) recognition and
cancer-induced inflammation has been
previously suggested (Escamilla-Tilch
et al., 2013), the specific mechanisms
through which tumors hijack pro-in-
flammatory pathways to promote tumor
growth remain unclear.
In an elegant study in this issue of Cell,
Nabet et al. (2017) address this conun-drum by building upon their previous
work, which demonstrated that stromal
cells induce interferon-stimulated genes
(ISGs) in a subset of aggressive, triple-
negative breast cancer (TNBC) cells via
exosome secretion, rendering these
breast cancer cells therapy resistant
(Boelens et al., 2014). The authors show
that inflammatory pathways normally
only activated in response to exoge-
nous, viral RNAs are instead ectopically
induced in cancer by deregulated release
of exposed endogenous 50 triphosphory-
lated double-stranded RNA in tumor
stroma exosomes (Nabet et al., 2017).
The unshielded non-coding RNAs en-
riched in exosomes from tumor-activated
stromal cells then act as DAMP signals,
triggering a feedback loop that activates
the pattern recognition receptor (PRR)
retinoic acid-inducible gene I (RIG-I) and
ISGs in breast cancer and innate immune
cells.
Since endogenous RNAs can act as
DAMPs in response to injury induced
by radiation, chemotherapy, or during
autoimmune diseases, Nabet et al. first
characterized the RNAs packaged in
exosomes released by fibroblasts co-
cultured with ISG-responsive breast can-
cer cells. Metabolic labeling and single
nucleotide polymorphism (SNP) analysis
confirmed that stromal RNA was trans-
ferred to breast cancer cells. Interest-
ingly, stromal exosomal RNA (exoRNA)
was enriched in endogenous non-codingCell 170, July 13, 2RNAs, including repeat and transposable
elements (ALU and SINE) and Y-RNA and
snRNA, as well as srpRNA. Importantly,
the authors demonstrated that an exposed
50 triphosphate (50 ppp)was responsible for
stromal exoRNA-mediated activation of
the RIG-I receptor, and thus ISG induction,
in breast cancer cells.
Next, using both chemical and genetic
ablation of RNA polymerase III (POL3)
function, Nabet et al. revealed that
POL3 is responsible for 50 ppp production
in stromal cells co-cultured with ISG-
responsive breast cancer. The authors
then devised a novel 50 ppp sequencing
method to identify the specific POL3-
driven exoRNA responsible for RIG-I
activation, utilizing enzymatic modifica-
tion of the 50 RNA end before constructing
their sequencing library. This ingenious
approach allowed Nabet et al. to deplete
RNAs lacking 50ppp modifications and
thus enrich for RNAs of interest, specif-
ically RN7SL1, a 50 ppp srpRNA with an
extensive secondary structure, normally
highly shielded in cells. Importantly, in
contrast to normal cytoplasmic RN7SL1,
the 50 ends of RN7SL1 packaged in stro-
mal exosomes derived from the breast
cancer cell co-culture were not protected
by RNA binding proteins (RBPs), such
as SRP9 and SRP14, accounting for its
unique capacity to stimulate RIG-I.
Thus, what is the mechanism respon-
sible for the unshielding of stromal exo-
some RN7SL1? The authors reasoned017 ª 2017 Published by Elsevier Inc. 223
Figure 1. Reciprocal Tumor-Stromal Activation Increases Unshielded RN7SL1 in Stromal Exosomes to Enhance Inflammation, Tumor
Growth, and Metastasis
(A) Heterotypic tumor-stroma interactions induce interferon-stimulated gene (ISGs) in a subset of breast cancer cells, called ISG responders (ISG-R). Cancer cell-
stromal cell contact and engagement of breast cancer NOTCH3 and stromal JAG1 increases exosome production and triggers stromal NOTCH1-MYC activation.
Whether tumors cells also release soluble factors and exosomes that further reinforce reciprocal communication remains to be determined. Stromal NOTCH1-
MYC signaling increases RNA polymerase III (POL3) transcriptional activity and, consequently, RN7SL1. The increase in RN7SL1 levels, in the absence of a
proportional increase in SRP9 and SRP14, which normally shield this transcript, markedly increases unshielded RN7SL1. Unshielded RN7SL1 is released in
stromal exosomes and transferred to ISG-R breast cancer cells, where it activates the pattern recognition receptor (PRR) RIG-I, leading to STAT1 activation and
ISG induction. Unshielded exosomal RN7SL1 also activates myeloid/dendritic cells, inducing CD40, CD86, PDL1, and MHCII expression. Unshielded exosomal
RN7SL1 and RIG-I activation promotes primary tumor growth and metastasis. Interestingly, viral particles contain endogenous non-viral RNAs, including
RN7SL1, but not SRPs (Telesnitsky and Wolin, 2016), which activate RIG-I in a manner similar to that of breast cancer exosomes.
(B) ISG non-responder (ISG-NR) breast cancer cells fail to enhance stromal exosome transfer and to induce ISGs upon tumor-stroma interactions. ISG-NRs do
not increase stromal RN7SL1 transcription or stromal exosome production. Shielding of RN7SL1 by SRP9 and SRP14 inhibits RIG-I activation and ISG induction.that a MYC-driven increase in POL3 tran-
scriptional activity results in an excess of
RN7SL1 (and other) 50 ppp transcripts,
without a proportional increase in the
amount of SRP9/SRP14 RNA binding
proteins, leading to accumulation of un-
shielded RN7SL1 in stromal exosomes.224 Cell 170, July 13, 2017Indeed, co-culture of breast cancer cells,
expressing the NOTCH ligand JAGGED1,
with NOTCH1-expressing stromal fibro-
blasts activates NOTCH and its down-
stream transcriptional targets, such as
MYC, in stromal cells (Figure 1). To com-
plete the vicious cycle in cancer pro-gression, transfer of unshielded stromal
exoRN7SL1 to breast cancer and immune
cells activates RIG-I signaling and in-
duces upregulation of maturation/acti-
vation markers by dendritic cells and
myeloid cells, events that are required
for ISG-responsive tumor growth and
lung metastasis in murine models of
breast cancer.
Lastly, confirming the clinical relevance
of their mechanistic studies, the authors
demonstrate that abundant POL3 and
RN7SL1 transcripts are present in exo-
somes isolated from the serum of cancer
patients. This finding suggests that these
molecules could serve as biomarkers of
inflammation and poor prognosis. More-
over, examination of exoRNA released
by tumor-associated fibroblasts isolated
from cancer patients revealed a signifi-
cant increase in unshielded exoRN7SL1,
as compared to healthy control fibro-
blasts. It would be interesting todetermine
whether this mechanism is commonly
activated in highly metastatic cancers
other than TNBC. Should a common
mechanism of PRR recognition be identi-
fied in a subset of aggressive cancers, it
would be crucial to further investigate the
features that distinguish responder versus
non-responder tumors and target them to
hinder cancer progression, since directly
blocking NOTCH activation in breast can-
cer has proven challenging due to ubiqui-
tous expression of NOTCH receptors and
their essential functions (Liu et al., 2016).
Nabet et al. demonstrate that aggres-
sive cancers can activate stromal cells,
inducing the release of endogenous exo-
somal RNAs that mimic viral components,to co-opt anti-viral immune responses
into promoting tumor growth and inflam-
mation. This comprehensive study opens
the door to future studies into the complex
interactions between DAMP signaling and
cancer—specifically, do other DAMPs
drive sterile inflammation during cancer
progression? How is interferon (IFN)
response activation, normally central to
anti-tumor responses, beneficial for can-
cer cells? Furthermore, is there a right
balance of IFN responses that restrains
rather than promotes tumor growth and
can it be harnessed to fight cancer?
Exosomes are ubiquitous messengers
in the intricate intercellular communica-
tion system established during cancer
progression. The central role of exosomes
in linking stromal activation and PRR
signaling in cancer, demonstrated by the
authors, begs the question of whether
exosomes carrying DAMPs are also
acting on disseminated tumor cells and
stromal cells at metastatic sites. Is uncap-
ped RNA (or other DAMPs) preferentially
shed in exosomes? And more broadly,
what is the role of DAMPs in metastasis,
and is this due to effects on tumor cells
or the immune system (or both)?
Importantly, the quality and strength of
the immune response to these exosomal
RNA DAMPs requires further evaluation.
How do exosomal DAMPs induce an im-mune response, what are the immune
subsets orchestrating it, and what is the
link to tumor progression andmetastasis?
Future studies addressing these ques-
tions will no doubt reinforce the idea that
exosomal DAMPs, such as RN7SL1, are
key factors regulating immune responses
during tumor progression.
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